---
title: Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer
nct_id: NCT01597999
overall_status: UNKNOWN
phase: PHASE4
sponsor: Mahidol University
study_type: INTERVENTIONAL
primary_condition: Invasive Breast Cancer
countries: Thailand
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01597999.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01597999"
ct_last_update_post_date: 2013-01-23
last_seen_at: "2026-05-12T06:36:53.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Benefits of Breast MRI for Predicting of Histopathologic Cell Type of Small Breast Cancer

**Official Title:** Accuracy of Magnetic Resonance Imaging (MRI) in Predicting Aggressiveness of Early Breast Cancer According to Molecular Subtypes Identified by ER PR and HER-2 Status

**NCT ID:** [NCT01597999](https://clinicaltrials.gov/study/NCT01597999)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 60
- **Lead Sponsor:** Mahidol University
- **Conditions:** Invasive Breast Cancer
- **Start Date:** 2011-02
- **Completion Date:** 2013-12
- **CT.gov Last Update:** 2013-01-23

## Brief Summary

This study examines the additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features.

## Detailed Description

Dedicated Contrast-enhanced Magnetic Resonance Imaging (DCE-MRI)

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** FEMALE
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Patients with invasive ductal carcinoma
* Patients undergoing DCE-MRI scan which are assessed according to BI-RADS lexicon
* Breast cancer patients with pathological diagnosed invasive ductal carcinoma with hormonal receptor (ER, PR and HER-2) response
* Patients who have signed on informed consent form Patients will undergo MRI imaging and the physicians will practice according to practice guidelines.

Exclusion Criteria:

* Patients under 18 years old or during pregnancy
* Patients with MRI's contraindications e.g. patients with cardiac pacemaker or are allergic to MRI contrast agent Patients with unstable clinical abnormality and might get unexpected clinical treatment
```

## Arms

- **No treatment** (OTHER) — Accuracy of magnetic resonance imaging (MRI) in predicting aggressiveness of early breast cancer according to molecular subtypes identified by ER PR and HER-2 status ( Additional benefits of magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features )

## Interventions

- **MRI** (RADIATION) — magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features

## Primary Outcomes

- **study the benefits of DCE-MRI using Gadovist in prognostic determination of early invasive breast cancer** _(time frame: 1 year)_ — The benefits of breast tumor diagnosis from DCE-MRI in early invasive breast cancer with poor prognostic features

## Secondary Outcomes

- **ascertain the accuracy of pre-operative DCE-MRI in terms of detection and characterization of breast cancer, as compared to tissue biopsy.** _(time frame: 1 year)_

## Locations (1)

- Faculty of Medicine Siriraj Hospital, Bangkoknoi, Bangkok, Thailand — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.faculty of medicine siriraj hospital|bangkoknoi|bangkok|thailand` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01597999.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01597999*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*